Compare Stocks: BMY, INDV, HCM, and VEC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$63.76 -1.0%	$63.50	$42.52 ▼ $68.64	$131.57B	0.23	7.60 million shs	6.50 million shs
HCM HUTCHMED	$13.12 -3.3%	$11.98	$9.77 ▼ $18.30	$2.37B	0.24	102,598 shs	45,161 shs
INDV Indivior	$34.51 -0.7%	$38.29	$22.22 ▼ $42.81	$4.10B	0.82	1.83 million shs	1.32 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.08%	-6.32%	+0.15%	+11.77%	+35.23%
HCM HUTCHMED	-3.32%	-7.02%	+5.21%	+19.71%	-16.49%
INDV Indivior	-0.75%	-0.92%	-10.20%	-10.32%	+41.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$63.76 -1.0%	$63.50	$42.52 ▼ $68.64	$131.57B	0.23	7.60 million shs	6.50 million shs
HCM HUTCHMED	$13.12 -3.3%	$11.98	$9.77 ▼ $18.30	$2.37B	0.24	102,598 shs	45,161 shs
INDV Indivior	$34.51 -0.7%	$38.29	$22.22 ▼ $42.81	$4.10B	0.82	1.83 million shs	1.32 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.08%	-6.32%	+0.15%	+11.77%	+35.23%
HCM HUTCHMED	-3.32%	-7.02%	+5.21%	+19.71%	-16.49%
INDV Indivior	-0.75%	-0.92%	-10.20%	-10.32%	+41.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.56	Moderate Buy	$66.33	4.03% Upside
HCM HUTCHMED	2.43	Hold	$14.87	13.31% Upside
INDV Indivior	2.86	Moderate Buy	$45.17	30.88% Upside

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and VEC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BMY Bristol Myers Squibb	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$60.00 ➝ $65.00
9/8/2026	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/3/2026	HCM HUTCHMED	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/18/2026	BMY Bristol Myers Squibb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/7/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/5/2026	BMY Bristol Myers Squibb	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	BMY Bristol Myers Squibb	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy
8/5/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/5/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.70	$8.05 per share	7.92	$9.09 per share	7.01
HCM HUTCHMED	$548.51M	4.17	$2.61 per share	5.03	$7.17 per share	1.83
INDV Indivior	$1.24B	3.29	$2.70 per share	12.78	($0.78) per share	-44.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$4.54	14.04	9.90	0.31	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
HCM HUTCHMED	$456.91M	N/A	N/A	59.64	N/A	N/A	N/A	N/A	N/A
INDV Indivior	$210M	$2.79	12.37	9.01	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)

Latest BMY, INDV, HCM, and VEC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	3.95%	+1.61%	55.51%	17 Years
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A

Latest BMY, INDV, HCM, and VEC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	1.89	1.53	1.38
HCM HUTCHMED	0.06	5.64	5.50
INDV Indivior	N/A	0.84	0.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
HCM HUTCHMED	8.82%
INDV Indivior	60.33%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
HCM HUTCHMED	3.60%
INDV Indivior	0.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
INDV Indivior	1,051	118.01 million	117.14 million	Not Optionable

BMY, INDV, HCM, and VEC Headlines

Recent News About These Companies

Wellington Management Group LLP Purchases Shares of 45,581 Indivior PLC $INDV

20 minutes ago | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $3.33 Million in Indivior PLC $INDV

September 10 at 5:11 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $7.99 Million Position in Indivior PLC $INDV

September 8 at 4:55 AM | marketbeat.com

Why Indivior Pharmaceuticals Inc. (INDV) is a top growth stock for the long term

August 31, 2026 | msn.com

Indivior Pharmaceuticals Inc. (INDV) loses 12.9% in 4 weeks, here's why a trend reversal may be around the corner

August 31, 2026 | msn.com

1,305,795 Shares in Indivior PLC $INDV Acquired by Newtyn Management LLC

August 31, 2026 | marketbeat.com

Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 31, 2026 | americanbankingnews.com

Cookson Peirce & Co. Inc. Invests $1.39 Million in Indivior PLC $INDV

August 31, 2026 | marketbeat.com

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Navellier & Associates Inc. Makes New $7.13 Million Investment in Indivior PLC $INDV

August 29, 2026 | marketbeat.com

Insider Buying: Indivior (NASDAQ:INDV) CAO Buys $53,535.00 in Stock

August 28, 2026 | insidertrades.com

Indivior (NASDAQ:INDV) CAO Woodrow Anderson Acquires 1,500 Shares

August 27, 2026 | marketbeat.com

Indivior PLC (NASDAQ:INDV) Receives Average Rating of "Moderate Buy" from Analysts

August 26, 2026 | marketbeat.com

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

August 21, 2026 | zacks.com

Should investors buy INDV as Sublocade growth meets rising risks?

August 21, 2026 | msn.com

Handelsbanken Fonder AB Takes $1.86 Million Position in Indivior PLC $INDV

August 18, 2026 | marketbeat.com

Here's why Indivior Pharmaceuticals Inc. (INDV) is a strong growth stock

August 13, 2026 | msn.com

Is Indivior Pharmaceuticals Inc. (INDV) a solid growth stock? 3 reasons to think "yes"

August 11, 2026 | msn.com

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

August 7, 2026 | businesswire.com

Insider Buying: Indivior (NASDAQ:INDV) CAO Acquires 1,500 Shares

August 6, 2026 | insidertrades.com

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

August 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and VEC Company Descriptions

Bristol Myers Squibb NYSE:BMY

$63.76 -0.65 (-1.01%)

Closing price 09/10/2026 03:59 PM Eastern

Extended Trading

$64.00 +0.23 (+0.37%)

As of 05:05 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

HUTCHMED NASDAQ:HCM

$13.12 -0.45 (-3.32%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$13.10 -0.02 (-0.16%)

As of 04:31 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Indivior NASDAQ:INDV

$34.51 -0.26 (-0.75%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$34.37 -0.14 (-0.40%)

As of 04:43 AM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and VEC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, INDV, HCM, and VEC Earnings

Compare Dividends

Latest BMY, INDV, HCM, and VEC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, INDV, HCM, and VEC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and VEC Company Descriptions

Bristol Myers Squibb NYSE:BMY

HUTCHMED NASDAQ:HCM

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and VEC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, INDV, HCM, and VEC Earnings

Compare Dividends

Latest BMY, INDV, HCM, and VEC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, INDV, HCM, and VEC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and VEC Company Descriptions

Bristol Myers Squibb NYSE:BMY

HUTCHMED NASDAQ:HCM

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools